Advisory Services Network LLC Acquires 13,038 Shares of Johnson & Johnson $JNJ

Advisory Services Network LLC raised its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 17.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 85,838 shares of the company’s stock after purchasing an additional 13,038 shares during the quarter. Advisory Services Network LLC’s holdings in Johnson & Johnson were worth $14,141,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Johnson & Johnson by 1.3% during the 2nd quarter. Vanguard Group Inc. now owns 237,047,859 shares of the company’s stock worth $36,209,060,000 after acquiring an additional 3,085,180 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Johnson & Johnson by 2.1% in the 2nd quarter. Geode Capital Management LLC now owns 60,609,476 shares of the company’s stock worth $9,227,988,000 after purchasing an additional 1,225,676 shares in the last quarter. Norges Bank purchased a new position in Johnson & Johnson during the 2nd quarter worth $4,877,174,000. Northern Trust Corp increased its position in Johnson & Johnson by 0.4% during the 1st quarter. Northern Trust Corp now owns 30,943,820 shares of the company’s stock valued at $5,131,723,000 after buying an additional 130,645 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in Johnson & Johnson by 2.7% in the second quarter. Bank of New York Mellon Corp now owns 23,802,503 shares of the company’s stock valued at $3,635,832,000 after buying an additional 620,039 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.8%

JNJ opened at $211.65 on Friday. The company has a fifty day moving average of $196.09 and a two-hundred day moving average of $177.25. The stock has a market capitalization of $509.93 billion, a price-to-earnings ratio of 20.43, a PEG ratio of 2.36 and a beta of 0.36. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $212.27. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 9th. Stockholders of record on Tuesday, November 25th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on JNJ shares. Sanford C. Bernstein upped their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. Wells Fargo & Company boosted their price objective on shares of Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a report on Friday. Bank of America raised their target price on Johnson & Johnson from $198.00 to $204.00 and gave the stock a “neutral” rating in a research note on Wednesday, October 15th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a report on Monday, October 20th. Finally, Argus set a $210.00 target price on Johnson & Johnson in a report on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $207.55.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.